Alzheimer disease. Dementia in Alzheimer's disease, atypical or mixed type
Conditions
Interventions
Intervention 1: Intervention group: Trehalose will be administrated intravenously (15 g/week) for 12 weeks in the intervention group. Intervention 2: Control group: Normal saline as a placebo will be
Sponsors
Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Mini-Mental State Examination (MMSE) score range from 10 to 23 Not having other cognitive disorders
Exclusion criteria
Exclusion criteria: MMSE score higher than 23 or lower than 10 The presence of other cognitive disorders which will be evaluated by clinical assessment and brain imaging Vascular dementia and Lewy body dementia Previous history of head trauma Use of alcohol and other drugs that affect cognitive functioning
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in CDR-SB and MMSE scores. Timepoint: At the beginning and end of the intervention trial (Day 0 and week 12). Method of measurement: Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) and Mini-Mental State Examination (MMSE) questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| Alterations in Alzheimer disease-related microRNA levels. Timepoint: Baseline and week 12. Method of measurement: Real-time quantitative PCR.;Alteration in serum levels of phosphorylated tau protein. Timepoint: Baseline and week 12. Method of measurement: ELISA.;Alteration in serum levels of Aß42. Timepoint: Baseline and week 12. Method of measurement: ELISA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmirhossein Sahebkar
Mashhad University of Medical Sciences
Outcome results
None listed